<DOC>
	<DOCNO>NCT03008616</DOCNO>
	<brief_summary>This study evaluate use Digoxin immune fab addition expectant management treatment severe preeclampsia compare placebo .</brief_summary>
	<brief_title>Study Efficacy Safety DigiFab® Antepartum Subjects With Severe Preeclampsia</brief_title>
	<detailed_description />
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Fetal gestational age 23 0/7 31 6/7 week Treated expectant management Meets ACOG criterion severe preeclampsia Willing able provide write , informed consent Decision deliver within 24 hour make Weight &gt; 150 kg Eclampsia Significant antecedent obstetrical problem Clinically significant fetal anomaly chromosomal abnormality Chronic renal disease Active hepatic disease , antiphospholipid antibody syndrome , lupus Unstable medical psychiatric disorder Need use digitalis like product History anaphylactic allergic reaction Prior use antibodies/fab fragment sheep Serum creatinine ≥ 2.0 mg/dL Platelet count &lt; 50,000 Pulmonary edema Estimated fetal weight &lt; 5th percentile</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>